New Jersey Trim Clinic vs Noom: GLP-1 vs App-Based Coaching in NJ
Published by New Jersey Trim Clinic · Updated 2025-12-06
Apples and Oranges
Noom is a behavioral app. New Jersey Trim Clinic is a medical program. If calorie tracking and color-coded food categories worked for you long-term, you wouldn't be reading this.
👉 Check If You Qualify in 2 Minutes
The Honest Reason Noom Stops Working
Noom asks you to out-discipline your biology. For most NJ patients with persistent food noise, that fails by month three — not because you didn't try, but because hunger hormones don't care about a streak counter.
GLP-1 therapy works on the actual biology. Once the food noise is quiet, the behavior changes Noom teaches actually start to stick.
👉 Book a Free Consultation · See $149/mo Pricing
Cost Comparison
- Noom: ~$70/month for the app alone, no medication.
- New Jersey Trim Clinic: $149/month all-inclusive — physician, medication, follow-ups, shipping.
For roughly twice the price you get the actual treatment, not a tracking journal.
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.
Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.
- NIH/NIDDK — Factors Affecting Weight & Health
Supports: Weight is influenced by lifestyle, sleep, medicines, health conditions, family history and other factors; insufficient sleep can affect hunger.
Evidence limits: This general guidance does not establish the cause of an individual patient's cravings, emotional eating, insulin resistance or weight changes.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
RESEARCH & REFERENCES
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. Diabetes, Obesity and Metabolism. 2021.
Research published in Diabetes, Obesity and Metabolism reported improvements in appetite and control of eating in a 20-week trial of semaglutide in adults with obesity.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.